Efficacy of cetuximab and mutant selective EGFR inhibitor WZ4002 in EGFR T790M and non-T790M models of erlotinib resistant non-small cell lung cancer

被引：1
|
作者：
Tricker, Erin M. [1 ]
Xu, Chunxiao [1 ]
Wong, Kwok-Kin [1 ]
Janne, Pasi A. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2595
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
    Kuang, Yanan
    Rogers, Andrew
    Yeap, Beow Y.
    Wang, Lilin
    Makrigiorgos, Mike
    Vetrand, Kristi
    Thiede, Sara
    Distel, Robert J.
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2009, 15 (08) : 2630 - 2636
  • [2] TGFa upregulation mediates growth retardation in EGFR T790M mutant non-small cell lung cancer
    Repellin, Claire E.
    Eser, Pinar O.
    Capelletti, Marzia
    Shimamura, Takeshi
    Ercan, Dalia
    Xu, Chunxiao
    Gray, Nathanael S.
    Wong, Kwok-Kin
    Janne, Pasi A.
    CANCER RESEARCH, 2016, 76
  • [3] REVERSAL OF RESISTANCE TO EGFR TYROSINE KINASE INHIBITOR BY EGFR T790M SPECIFIC SIRNA IN NON-SMALL CELL LUNG CANCER
    Lee, Choon-Taek
    Park, Mi-Young
    Eo, Eun Young
    Park, Jong Sun
    Cho, Young Jae
    Yoon, Ho-Il
    Lee, Jae Ho
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S458 - S458
  • [4] Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
    John, Thomas
    Bowden, Jeffrey J.
    Clarke, Stephen
    Fox, Stephen B.
    Garrett, Kerryn
    Horwood, Keith
    Karapetis, Christos S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (04) : 296 - 303
  • [5] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [6] Targeting the EGFR T790M mutation in non-small-cell lung cancer
    Normanno, Nicola
    Maiello, Monica Rosaria
    Chicchinelli, Nicoletta
    Iannaccone, Alessia
    Esposito, Claudia
    De Cecio, Rossella
    D'alessio, Amelia
    De Luca, Antonella
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
  • [7] Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
    Takeshi Masuda
    Satoru Miura
    Yuki Sato
    Motoko Tachihara
    Akihiro Bessho
    Atsushi Nakamura
    Taichi Miyawaki
    Kohei Yoshimine
    Masahide Mori
    Hideaki Shiraishi
    Kosuke Hamai
    Koji Haratani
    Sumiko Maeda
    Eriko Tabata
    Chiyoe Kitagawa
    Junko Tanizaki
    Takumi Imai
    Shohei Nogami
    Nobuyuki Yamamoto
    Kazuhiko Nakagawa
    Noboru Hattori
    Scientific Reports, 13
  • [8] Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
    Masuda, Takeshi
    Miura, Satoru
    Sato, Yuki
    Tachihara, Motoko
    Bessho, Akihiro
    Nakamura, Atsushi
    Miyawaki, Taichi
    Yoshimine, Kohei
    Mori, Masahide
    Shiraishi, Hideaki
    Hamai, Kosuke
    Haratani, Koji
    Maeda, Sumiko
    Tabata, Eriko
    Kitagawa, Chiyoe
    Tanizaki, Junko
    Imai, Takumi
    Nogami, Shohei
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Hattori, Noboru
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [9] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [10] IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and non-T790M gefitinib-resistant lung cancer cell lines.
    Park, Joon Oh
    Zhao Feng
    Zejnullahu, Kreshnik
    Normant, Emmanuel
    Engelman, Jeffrey A.
    Johnson, Bruce E.
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S361 - S361
12345